8:18 AM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kancera's KAND567 well tolerated in Phase I

Kancera AB (SSE:KAN) reported data from a Phase I trial in 82 healthy volunteers showing that lymphoma, inflammation and cardiovascular disease candidate KAND567 (AZD8797) was well tolerated.

The double-blind, placebo-controlled trial evaluated single doses...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >